OXP’s NSAID portfolio continues to progress with OXPzeroTM Naproxen having recently achieved bioequivalence and begun an endoscopy pilot clinical trial. The development of a chewable OXPzeroTM Ibuprofen has also been completed. We update our forecasts in this note for the £20m equity capital raise which should enable OXP to negotiate commercialisation deals from a position of strength whilst it continues to progress development of its product portfolio. Increased efforts are being made with OXPz ....
